AGN

ARGENICA FPO [AGN]
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
Healthcare · ASX Small Cap
$0.1800 -7.7%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when AGN triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track AGN — Free

Active Signals

Bullish Signals

  • MACD momentum is losing steam
  • Above-average volume (1.9x) on a red day — sellers in control
  • Smart money may be accumulating — volume is flowing in even though price hasn't moved yet
  • Drifting lower — down 10.0% over the last 5 days
  • Adequate cash runway (6 quarters)
  • 4C filed 2026-07-23
  • Low P/S ratio (4.3x)
  • Strong revenue growth (+1179%)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +1179% — the top line is moving in the right direction
  • Altman Z-Score distress zone (1.77 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-25%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 35% over the past year
  • The bigger volume days are the down days — volume-weighted momentum is negative (-0.33%/day)
Ask Scout AI about AGN
"What's driving AGN today?" "How does AGN compare to peers?" "Key risks for AGN?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Appendix 4G & Corporate Governance Statement
NONE Notification of cessation of securities - AGN
LOW Appendix 4E & Annual Report to 30 June 2026
LOW Investor Presentation - Techknow Conference
LOW Quarterly Activities/Appendix 4C Cash Flow Report

Recent ASX Announcements

2026-08-26 Appendix 4G & Corporate Governance Statement
2026-08-26 Appendix 4E & Annual Report to 30 June 2026 PRICE SENSITIVE
2026-08-13 Notification of cessation of securities - AGN
2026-07-26 Investor Presentation - Techknow Conference
2026-07-23 Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE

Key Metrics

$23.8M
Market Cap
74K
Avg Volume
1.9x
Vol Ratio
$0.09 — $0.38
52-Week Range
N/A
Short Interest
6 qtrs
Cash Runway
-20.8%
ROE
-24.9%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 76%
LLeader vs LaggardpassRS: 19
IInstitutional SponsorshipweakInst: 1%
MMarket DirectionneutralNeutral

Sector: Healthcare

113 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
REG -27.0%CAN +25.0%BIT -20.0%MEM +20.0%CMP -14.6%
Compare:AGN vs REGAGN vs CANAGN vs BIT
Scout Pro — Deeper Analysis for AGN
Try Pro free for 30 days
Share this analysis

Track AGN and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required